<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Ziprasidone</strong></td></tr><tr><th>Accession Number</th><td><strong>DB00246</strong>&#160; (APRD00540)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved</td></tr><tr><th>Description</th><td><p>Ziprasidone (marketed as Geodon, Zeldox) was the fifth atypical antipsychotic to gain <span class="caps">FDA</span> approval (February 2001). Ziprasidone is Food and Drug Administration (<span class="caps">FDA</span>) approved for the treatment of schizophrenia, and the intramuscular injection form of ziprasidone is approved for acute agitation in schizophrenic patients. Ziprasidone has also received approval for acute treatment of mania associated with bipolar disorder. [Wikipedia]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB00246/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB00246/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00246.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00246.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00246.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00246.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB00246.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB00246">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Salts</th><td class="table-container"><table class="inner">
  <thead>
    <tr>
      <th>Name/CAS</th>
      <th>Structure</th>
      <th>Properties</th>
      <th></th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>
          <strong>Ziprasidone hydrochloride</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000810/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000810/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: ZCBZSCBNOOIHFP-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 466.099702136</li>
              <li>Average Mass: 467.412</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000810">DBSALT000810</a></td>
      </tr>
      <tr>
        <td>
          <strong>Ziprasidone mesylate trihydrate</strong>
          <div class="cas"></div>
        </td>
        <td><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DBSALT000811/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DBSALT000811/thumb.png"></a></td>
        <td>
            <ul>
              <li>InChI Key: WLQZEFFFIUHSJB-UHFFFAOYSA-N</li>
              <li>Monoisotopic Mass: 562.132268453</li>
              <li>Average Mass: 563.087</li>
            </ul>
        </td>
        <td><a class="btn btn-default btn-xs" href="/salts/DBSALT000811">DBSALT000811</a></td>
      </tr>
  </tbody>
</table></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Geodon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Zeldox</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/antipsychotic-agents">Antipsychotic Agents</a></li></ul></td></tr><tr><th>CAS number</th><td>146939-27-7</td></tr><tr><th>Weight</th><td>Average: 412.936<br>Monoisotopic: 412.112459711</td></tr><tr><th>Chemical Formula</th><td>C<sub>21</sub>H<sub>21</sub>ClN<sub>4</sub>OS</td></tr><tr><th>InChI Key</th><td>MVWVFYHBGMAFLY-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C21H21ClN4OS/c22-17-13-18-15(12-20(27)23-18)11-14(17)5-6-25-7-9-26(10-8-25)21-16-3-1-2-4-19(16)28-24-21/h1-4,11,13H,5-10,12H2,(H,23,27)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">5-{2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl}-6-chloro-2,3-dihydro-1H-indol-2-one</div></td></tr><tr><th>SMILES</th><td><div class="wrap">ClC1=C(CCN2CCN(CC2)C2=NSC3=CC=CC=C23)C=C2CC(=O)NC2=C1</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Benzothiazoles</td></tr><tr><th>Subclass</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Direct parent</th><td>Benzothiazoles</td></tr><tr><th>Alternative parents</th><td>Indolines; Phenethylamines; Chlorobenzenes; Piperazines; Aryl Chlorides; Diazinanes; Aminothiazoles; Tertiary Amines; Secondary Carboxylic Acid Amides; Polyamines; Carboxylic Acids; Organochlorides</td></tr><tr><th>Substituents</th><td>chlorobenzene; 1,4-diazinane; aryl halide; piperazine; benzene; 1,2-thiazolamine; aryl chloride; thiazole; azole; carboxamide group; tertiary amine; secondary carboxylic acid amide; carboxylic acid; carboxylic acid derivative; polyamine; amine; organohalogen; organonitrogen compound; organochloride</td></tr><tr><th>Classification description</th><td>This compound belongs to the benzothiazoles. These are organic compounds containing a benzene fused to a thiazole ring (a five-member ring with four carbon atoms, one nitrogen atom and one sulfur atom).</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the treatment of schizophrenia and related psychotic disorders.</td></tr><tr><th>Pharmacodynamics</th><td>Ziprasidone is a psychotropic agent belonging to the chemical class of benzisoxazole derivatives and is indicated for the treatment of schizophrenia. Ziprasidone is a selective monoaminergic antagonist with high affinity for the serotonin Type 2 (5HT2), dopamine Type 2 (D2), 1 and 2 adrenergic, and H1 histaminergic receptors. Ziprasidone acts as an antagonist at other receptors, but with lower potency. Antagonism at receptors other than dopamine and 5HT2 with similar receptor affinities may explain some of the other therapeutic and side effects of Ziprasidone. Ziprasidone's antagonism of muscarinic M1-5 receptors may explain its anticholinergic effects. Ziprasidone's antagonism of histamine H1 receptors may explain the somnolence observed with this drug. Ziprasidone's antagonism of adrenergic a1 receptors may explain the orthostatic hypotension observed with this drug. Ziprasidone functions as an antagonist at the Dopamine D2 , 5HT-2A , and 5HT-1D receptors, and as an agonist at the 5HT-1A receptor. Ziprasidone also inhibits synaptic reuptake of serotonin and norepinephrine.</td></tr><tr><th>Mechanism of action</th><td>Ziprasidone's antipsychotic activity is likely due to a combination of its antagonistic function at D2 receptors in the mesolimbic pathways and at 5HT2A receptors in the frontal cortex. Alleviation of positive symptoms is due to antagonism at D2 receptors while relief of negative symptoms are due to 5HT2A antagonism.</td></tr><tr><th>Absorption</th><td>~60%</td></tr><tr><th>Volume of distribution</th><td><ul>
	<li>1.5 L/kg</li>
</ul></td></tr><tr><th>Protein binding</th><td>99%</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Hepatic</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Ziprasidone</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002638" target="_blank">Cytochrome P450 3A4</a></li></ul></td><td><a href="/metabolites/DBMET00400">benzisothiazole piperazine</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/403">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Ziprasidone is extensively metabolized after oral administration with only a small amount excreted in the urine (</td></tr><tr><th>Half life</th><td>7 hours</td></tr><tr><th>Clearance</th><td><ul>
	<li>7.5 mL/min/kg</li>
</ul></td></tr><tr><th>Toxicity</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>1.0</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9759</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              +
        </td>
        <td>0.8867</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.7167</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Inhibitor
        </td>
        <td>0.8052</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Inhibitor
        </td>
        <td>0.6419</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Inhibitor
        </td>
        <td>0.5325</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7972</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9117</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.7408</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Inhibitor</td>
        <td>0.6576</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Inhibitor</td>
        <td>0.6329</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7151</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Inhibitor</td>
        <td>0.8086</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.7723</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>High CYP Inhibitory Promiscuity</td>
        <td>0.9567</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.6273
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.8672
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            1.0
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          2.5877 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.6826
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Inhibitor 
        </td>
        <td>
            0.7753
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Pfizer inc</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.benvenue.com">Ben Venue Laboratories Inc.</a></li>
<li><a href="http://www.cardinal.com">Cardinal Health</a></li>
<li>Comprehensive Consultant Services Inc.</li>
<li>Kaiser Foundation Hospital</li>
<li>Lake Erie Medical and Surgical Supply</li>
<li><a href="http://www.nucarerx.com">Nucare Pharmaceuticals Inc.</a></li>
<li><a href="http://www.pfizer.com">Pfizer Inc.</a></li>
<li><a href="http://www.pharmaciaupjohn.com">Pharmacia Inc.</a></li>
<li><a href="http://www.physicianstotalcare.com">Physicians Total Care Inc.</a></li>
<li>Prepackage Specialists</li>
<li><a href="http://www.rebelrx.com">Rebel Distributors Corp.</a></li>
<li><a href="http://www.remedyrepack.com">Remedy Repack</a></li>
<li>Resource Optimization and Innovation LLC</li>
<li><a href="http://statrxusa.exporterus.com">Stat Rx Usa</a></li>
<li>US Pharmaceutical Group</li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr><tr><td>Powder, for solution</td><td>Intramuscular</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB00106">Abarelix</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00915">Amantadine</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, amantadine. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB01118">Amiodarone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00321">Amitriptyline</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00543">Amoxapine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00714">Apomorphine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01169">Arsenic trioxide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB06697">Artemether</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06216">Asenapine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00207">Azithromycin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01200">Bromocriptine</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, bromocriptine. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB00564">Carbamazepine</a></td><td>Increases the effect and toxicity of ziprasidone</td></tr><tr><td><a href="/drugs/DB00477">Chlorpromazine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00604">Cisapride</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00215">Citalopram</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01211">Clarithromycin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01242">Clomipramine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01254">Dasatinib</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01151">Desipramine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00280">Disopyramide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00204">Dofetilide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00757">Dolasetron</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01184">Domperidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00843">Donepezil</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01142">Doxepin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB04855">Dronedarone</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy is contraindicated. </td></tr><tr><td><a href="/drugs/DB00450">Droperidol</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00199">Erythromycin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01175">Escitalopram</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01195">Flecainide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00196">Fluconazole</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00472">Fluoxetine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00875">Flupentixol</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00529">Foscarnet</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00674">Galantamine</a></td><td>Possible antagonism of action</td></tr><tr><td><a href="/drugs/DB01044">Gatifloxacin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01218">Halofantrine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00502">Haloperidol</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00308">Ibutilide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB04946">Iloperidone</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00458">Imipramine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00808">Indapamide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00270">Isradipine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01026">Ketoconazole</a></td><td>Ketoconazole increases the effect and toxicity of ziprasidone</td></tr><tr><td><a href="/drugs/DB01235">L-DOPA</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, levodopa. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB01259">Lapatinib</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01137">Levofloxacin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00408">Loxapine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB06708">Lumefantrine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00934">Maprotiline</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00358">Mefloquine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00933">Mesoridazine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00333">Methadone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01403">Methotrimeprazine</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00218">Moxifloxacin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB04868">Nilotinib</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01059">Norfloxacin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00540">Nortriptyline</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00104">Octreotide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB06589">Pazopanib</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00738">Pentamidine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00556">Perflutren</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01186">Pergolide</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pergolide. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB01100">Pimozide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00413">Pramipexole</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, pramipexole. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB01599">Probucol</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01035">Procainamide</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01182">Propafenone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00344">Protriptyline</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01224">Quetiapine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00908">Quinidine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00468">Quinine</a></td><td>Additive QTc-prolongation may occur. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00243">Ranolazine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00734">Risperidone</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB06176">Romidepsin</a></td><td>Additive QTc-prolongation may occur increasing the risk of life-threatening ventricular arrhythmias and torsade de pointes. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00268">Ropinirole</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, ropinirole. Consider alternate therapy or monitor for worsening of movement disorder. </td></tr><tr><td><a href="/drugs/DB05271">Rotigotine</a></td><td>The atypical antipsychotic, ziprasidone, may antagonize the effect of the dopamine agonist, rotigotine. Consider alternate therapy or monitor for worsening of movement disorder.</td></tr><tr><td><a href="/drugs/DB00489">Sotalol</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01208">Sparfloxacin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB01268">Sunitinib</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00382">Tacrine</a></td><td>Tacrine, a central acetylcholinesterase inhibitor, may augment the central neurotoxic effect of antipsychotics such as Ziprasidone. Monitor for extrapyramidal symptoms.</td></tr><tr><td><a href="/drugs/DB00864">Tacrolimus</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB06402">Telavancin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated.</td></tr><tr><td><a href="/drugs/DB00976">Telithromycin</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB04844">Tetrabenazine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00679">Thioridazine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01623">Thiothixene</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00539">Toremifene</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00726">Trimipramine</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Ziprasidone, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr><tr><td><a href="/drugs/DB00582">Voriconazole</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB02546">Vorinostat</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB01624">Zuclopenthixol</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08919">Zuclopenthixol acetate</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr><tr><td><a href="/drugs/DB08920">Zuclopenthixol decanoate</a></td><td>Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy should be avoided.</td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><ul><li>Avoid alcohol.</li></ul></td></tr></tbody></table>